https://www.contagionlive.com/view/additional-doses-of-rsv-monoclonal-antibody-being-made-available-in-january
The unprecedented demand for the pediatric RSV immunization, nirsevimab-alip, has resulted in a dramatic uptake in production.
Create an account or login to join the discussion